SHAREHOLDER ALERT: WeissLaw LLP Investigates Pandion Therapeutics, Inc.

 
 

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pandion Therapeutics, Inc. ("Pandion" or the "Company") (NASDAQ: PAND) in connection with the proposed all-cash acquisition of the Company by Merck Sharp & Dohme Corp. (NYSE: MRK).  Under the terms of the merger agreement, Pandion shareholders will receive $60.00 in cash for each share of Pandion common stock that they own.  The transaction is valued at approximately $1.85 billion .

 
 

  WeissLaw LLP (PRNewsfoto/WeissLaw LLP) 

 
 

   If you own PAND shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:   

 

  https://www.weisslawllp.com/PAND/  

 

   Or please contact:
 
   Joshua Rubin, Esq.  
WeissLaw LLP
1500 Broadway, 16 th Floor
New York , NY  10036
(212) 682-3025
  (888) 593-4771
stockinfo@weisslawllp.com  
 

 

WeissLaw LLP is investigating whether (i) Pandion's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $60.00 per-share merger consideration adequately compensates Pandion's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at   stockinfo@weisslawllp.com   

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-pandion-therapeutics-inc-301235990.html  

 

SOURCE WeissLaw LLP

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×